Loading…
Reported covered position: Sen. Kay Bailey Hutchison (TX): Military Legislative Assistant and Foreign Policy Advisor; Rep. Jeff Miller (FL-01): Military Legislative Assistant
How to read the money
Income and expense are whole-filing amounts associated with this lobbyist, not personal compensation or an allocated share.
No topic inference: each bill number appears in source LDA issue text assigned to this lobbyist.
Medicaid VBPs for Patients Act
Client: ASTELLAS GENE THERAPIES, INC. A DELAWARE CORPORATION · Firm: ASTELLAS GENE THERAPIES, INC. A DELAWARE CORPORATION
Transparency Policy Issues, Medicare Part D, International Reference Pricing, Oncology Screening Awareness, Value-based Payment Arrangements for Gene Therapy (no specific bills); H.R. 2666 MVP Act, Medicaid Drug Rebate Program.
Elijah E. Cummings Lower Drug Costs Now Act
Client: ASTELLAS GENE THERAPIES, INC. A DELAWARE CORPORATION · Firm: ASTELLAS GENE THERAPIES, INC. A DELAWARE CORPORATION
Specific issues are shown only where the LDA source assigned them to this lobbyist. Targets apply to the associated filing.
ASTELLAS GENE THERAPIES, INC. A DELAWARE CORPORATION via ASTELLAS GENE THERAPIES, INC. A DELAWARE CORPORATION
2023 · fourth_quarter · Q4
Transparency Policy Issues, Medicare Part D, International Reference Pricing, Oncology Screening Awareness, Value-based Payment Arrangements for Gene Therapy (no specific bills); H.R. 2666 MVP Act, Medicaid Drug Rebate Program.
Value of Prescription Drugs, Drug pricing, Biopharmaceutical Innovation and Patient Policy Issues (no specific bills). Issues related to Patient Drug User Fee Reauthorization (no specific bills). Issues related to cell and gene therapy (no specific bills).
Source: Senate LDA
Gene therapy issues, value-based pricing, Prescription Drug Pricing Reduction Act of 2021, Elijah Cummings Lower Drug Costs Now Act (H.R. 3)
Prescription Drug Pricing Reduction Act of 2020
Client: ASTELLAS GENE THERAPIES, INC. A DELAWARE CORPORATION · Firm: ASTELLAS GENE THERAPIES, INC. A DELAWARE CORPORATION
Gene therapy issues, value-based pricing, Prescription Drug Pricing Reduction Act of 2020 (S.4199)
Prescription Drug Pricing Reduction Act of 2020
Client: ASTELLAS GENE THERAPIES, INC. A DELAWARE CORPORATION · Firm: ASTELLAS GENE THERAPIES, INC. A DELAWARE CORPORATION
Gene therapy issues, value-based pricing, Prescription Drug Pricing Reduction Act of 2020 (S.4199)
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ASTELLAS GENE THERAPIES, INC. A DELAWARE CORPORATION via ASTELLAS GENE THERAPIES, INC. A DELAWARE CORPORATION
2023 · third_quarter · Q3
Transparency Policy Issues, Medicare Part D, Coverage Gap, Rebate Reform, Out-of-Pocket Costs, International Reference Pricing, Oncology Screening Awareness, Value-based Payment Arrangements for Gene Therapy (no specific bills).
Value of Prescription Drugs, Drug pricing, Biopharmaceutical Innovation and Patient Policy Issues (no specific bills). Issues related to Patient Drug User Fee Reauthorization (no specific bills).
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ASTELLAS GENE THERAPIES, INC. A DELAWARE CORPORATION via ASTELLAS GENE THERAPIES, INC. A DELAWARE CORPORATION
2023 · second_quarter · Q2
Transparency Policy Issues, Medicare Part D, Coverage Gap, Rebate Reform, Out-of-Pocket Costs, International Reference Pricing, Oncology Screening Awareness, Value-based Payment Arrangements for Gene Therapy (no specific bills).
Value of Prescription Drugs, Drug pricing, Biopharmaceutical Innovation and Patient Policy Issues (no specific bills). Issues related to Patient Drug User Fee Reauthorization (no specific bills).
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ASTELLAS GENE THERAPIES, INC. A DELAWARE CORPORATION via ASTELLAS GENE THERAPIES, INC. A DELAWARE CORPORATION
2023 · first_quarter · Q1
Value of Prescription Drugs, Drug pricing, Biopharmaceutical Innovation and Patient Policy Issues (no specific bills). Issues related to Patient Drug User Fee Reauthorization (no specific bills).
Transparency Policy Issues, Medicare Part D, Coverage Gap, Rebate Reform, Out-of-Pocket Costs, International Reference Pricing, Oncology Screening Awareness, Value-based Payment Arrangements for Gene Therapy (no specific bills).
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ASTELLAS GENE THERAPIES, INC. A DELAWARE CORPORATION via ASTELLAS GENE THERAPIES, INC. A DELAWARE CORPORATION
2022 · fourth_quarter · Q4
Transparency Policy Issues, Medicare Part D, Coverage Gap, Rebate Reform, Out-of-Pocket Costs, International Reference Pricing, Oncology Screening Awareness, Value-based Payment Arrangements for Gene Therapy (no specific bills).
Value of Prescription Drugs, Drug pricing, Biopharmaceutical Innovation and Patient Policy Issues (no specific bills). Issues related to Patient Drug User Fee Reauthorization (no specific bills).
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ASTELLAS GENE THERAPIES, INC. A DELAWARE CORPORATION via ASTELLAS GENE THERAPIES, INC. A DELAWARE CORPORATION
2022 · third_quarter · Q3
Transparency Policy Issues, Medicare Part D, Coverage Gap, Rebate Reform, Out-of-Pocket Costs, International Reference Pricing, Oncology Screening Awareness, Value-based Payment Arrangements for Gene Therapy (no specific bills).
Value of Prescription Drugs, Drug pricing, Biopharmaceutical Innovation and Patient Policy Issues (no specific bills). Issues related to Patient Drug User Fee Reauthorization (no specific bills).
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ASTELLAS GENE THERAPIES, INC. A DELAWARE CORPORATION via ASTELLAS GENE THERAPIES, INC. A DELAWARE CORPORATION
2022 · second_quarter · Q2
Transparency Policy Issues, Medicare Part D, Coverage Gap, Rebate Reform, Out-of-Pocket Costs, International Reference Pricing, Oncology Screening Awareness, Value-based Payment Arrangements for Gene Therapy (no specific bills).
Value of Prescription Drugs, Drug pricing, Biopharmaceutical Innovation and Patient Policy Issues (no specific bills). Issues related to Patient Drug User Fee Reauthorization (no specific bills).
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ASTELLAS GENE THERAPIES, INC. A DELAWARE CORPORATION via ASTELLAS GENE THERAPIES, INC. A DELAWARE CORPORATION
2022 · second_quarter · RA
Transparency Policy Issues, Medicare Part D, Coverage Gap, Rebate Reform, Out-of-Pocket Costs, International Reference Pricing, Oncology Screening Awareness, Value-based Payment Arrangements for Gene Therapy; Value of Prescription Drugs, Drug pricing, Biopharmaceutical Innovation and Policy Issues, Issues related to Patient Drug User Fee Reauthorization.
Transparency Policy Issues, Medicare Part D, Coverage Gap, Rebate Reform, Out-of-Pocket Costs, International Reference Pricing, Oncology Screening Awareness, Value-based Payment Arrangements for Gene Therapy; Value of Prescription Drugs, Drug pricing, Biopharmaceutical Innovation and Policy Issues, Issues related to Patient Drug User Fee Reauthorization.
ASTELLAS GENE THERAPIES, INC. A DELAWARE CORPORATION via ASTELLAS GENE THERAPIES, INC. A DELAWARE CORPORATION
2022 · second_quarter · RA
Transparency Policy Issues, Medicare Part D, Coverage Gap, Rebate Reform, Out-of-Pocket Costs, International Reference Pricing, Oncology Screening Awareness, Value-based Payment Arrangements for Gene Therapy; Value of Prescription Drugs, Drug pricing, Biopharmaceutical Innovation and Policy Issues, Issues related to Patient Drug User Fee Reauthorization.
Transparency Policy Issues, Medicare Part D, Coverage Gap, Rebate Reform, Out-of-Pocket Costs, International Reference Pricing, Oncology Screening Awareness, Value-based Payment Arrangements for Gene Therapy; Value of Prescription Drugs, Drug pricing, Biopharmaceutical Innovation and Policy Issues, Issues related to Patient Drug User Fee Reauthorization.
ASTELLAS GENE THERAPIES, INC. A DELAWARE CORPORATION via ASTELLAS GENE THERAPIES, INC. A DELAWARE CORPORATION
2021 · first_quarter · 1T
Gene therapy issues, value-based pricing, Prescription Drug Pricing Reduction Act of 2021, Elijah Cummings Lower Drug Costs Now Act (H.R. 3)
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ASTELLAS GENE THERAPIES, INC. A DELAWARE CORPORATION via ASTELLAS GENE THERAPIES, INC. A DELAWARE CORPORATION
2020 · fourth_quarter · Q4
Gene therapy issues, value-based pricing, Prescription Drug Pricing Reduction Act of 2020 (S.4199)
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ASTELLAS GENE THERAPIES, INC. A DELAWARE CORPORATION via ASTELLAS GENE THERAPIES, INC. A DELAWARE CORPORATION
2020 · third_quarter · Q3
Gene therapy issues, value-based pricing, Prescription Drug Pricing Reduction Act of 2020 (S.4199)
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ASTELLAS GENE THERAPIES, INC. A DELAWARE CORPORATION via ASTELLAS GENE THERAPIES, INC. A DELAWARE CORPORATION
2020 · third_quarter · RR
Issues related to expanding access for cell and gene therapies, Medicare, Medicaid, and other general healthcare issues
Issues related to expanding access for cell and gene therapies, Medicare, Medicaid, and other general healthcare issues